AMGN:NSD-Amgen Inc (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 271.66

Change

0.00 (0.00)%

Market Cap

USD 151.21B

Volume

2.53M

Analyst Target

USD 262.76
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-24 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

N/A

USD 218.30B
SNY Sanofi ADR

N/A

USD 126.38B
GILD Gilead Sciences Inc

N/A

USD 122.21B
BIIB Biogen Inc

N/A

USD 17.35B
GRFS Grifols SA ADR

N/A

USD 5.91B
AMRN Amarin Corporation PLC

N/A

USD 0.23B
MIRA MIRA Pharmaceuticals, Inc. Com..

N/A

USD 0.02B
SCLX Scilex Holding Company

N/A

N/A
SCLXW Scilex Holding Company

N/A

N/A

ETFs Containing AMGN

2B70:F iShares NASDAQ US Biotech.. 7.95 % 0.00 %

N/A

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 7.91 % 0.00 %

N/A

USD 0.52B
BTEC:SW iShares Nasdaq US Biotech.. 7.89 % 0.00 %

N/A

N/A
UBIO 6.41 % 0.95 %

N/A

N/A
MEDX Horizon Kinetics Medical .. 5.91 % 0.00 %

N/A

N/A
LIFE-B:CA Evolve Global Healthcare .. 5.45 % 0.00 %

N/A

N/A
ZWHC:CA BMO Covered Call Health C.. 5.07 % 0.00 %

N/A

N/A
NDJI 4.95 % 0.00 %

N/A

N/A
LIFE-U:CA Evolve Global Healthcare .. 4.94 % 0.00 %

N/A

N/A
DOGG First Trust Exchange-Trad.. 4.75 % 0.00 %

N/A

USD 0.03B
YALL God Bless America ETF 4.70 % 0.00 %

N/A

N/A
ZWA:CA BMO Covered Call Dow Jone.. 4.60 % 0.72 %

N/A

CAD 0.20B
ZDJ:CA BMO Dow Jones Industrial .. 4.55 % 0.26 %

N/A

CAD 0.44B
CSINDU:SW iShares VII PLC - iShares.. 4.55 % 0.00 %

N/A

USD 1.55B
CBUF:F iShares V Public Limited .. 4.40 % 0.00 %

N/A

N/A
EXI3:XETRA iShares Dow Jones Industr.. 4.38 % 0.00 %

N/A

USD 0.30B
WHCS:SW iShares MSCI World Health.. 4.21 % 0.00 %

N/A

N/A
XGSD:SW Xtrackers Stoxx Global Se.. 3.39 % 0.00 %

N/A

USD 0.68B
WH2E:XETRA Invesco S&P World Health .. 3.35 % 0.00 %

N/A

N/A
FDV First Trust Capital Stren.. 3.17 % 0.00 %

N/A

N/A
IUHC:SW iShares S&P 500 Health Ca.. 3.12 % 0.00 %

N/A

N/A
GXLV:LSE SPDR® S&P® U.S. Health .. 3.11 % 0.00 %

N/A

N/A
SXLV:SW SPDR S&P U.S. Health Care.. 3.06 % 0.00 %

N/A

N/A
ZPDH:F SPDR S&P U.S. Health Care.. 3.05 % 0.00 %

N/A

USD 0.40B
XLV Health Care Select Sector.. 3.02 % 0.13 %

N/A

USD 33.98B
HEAL:CA 2.96 % 0.00 %

N/A

N/A
XUHC:F Xtrackers (IE) Public Lim.. 2.95 % 0.00 %

N/A

USD 0.85B
XUHC:SW 2.95 % 0.00 %

N/A

N/A
NZRO 2.90 % 0.00 %

N/A

N/A
FHLC Fidelity® MSCI Health Ca.. 2.61 % 0.08 %

N/A

USD 2.37B
CURE:AU ETFS S&P Biotech ETF 2.44 % 0.00 %

N/A

USD 0.04B
UVDV 2.35 % 0.00 %

N/A

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.33 % 0.00 %

N/A

N/A
CURE Direxion Daily Healthcare.. 2.30 % 1.06 %

N/A

USD 0.12B
USRI:LSE 1.80 % 0.00 %

N/A

N/A
XLVE:CA 1.72 % 0.00 %

N/A

N/A
ZDY.U:CA 1.63 % 0.33 %

N/A

N/A
HYLG 1.45 % 0.00 %

N/A

N/A
LESW:LSE 1.25 % 0.00 %

N/A

N/A
XAMB:F Amundi Index Solutions - .. 1.14 % 0.00 %

N/A

N/A
SF1CHA:SW 1.09 % 0.00 %

N/A

N/A
F1ESG:SW UBS(Lux)Fund Solutions .. 1.09 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

N/A

USD 0.34B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD 0.05B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD 3.16M
DDM ProShares Ultra Dow30 0.00 % 0.95 %

N/A

N/A
DEW WisdomTree Global High Di.. 0.00 % 0.58 %

N/A

N/A
DIA SPDR Dow Jones Industrial.. 0.00 % 0.17 %

N/A

N/A
DJD Invesco Dow Jones Industr.. 0.00 % 0.09 %

N/A

N/A
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 5.43B
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

N/A

N/A
LABS 0.00 % 0.45 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

N/A

USD 0.53B
LNGR 0.00 % 0.50 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

N/A
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

N/A

USD 0.01B
HONR 0.00 % 0.65 %

N/A

N/A
VSL 0.00 % 0.65 %

N/A

N/A
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

N/A
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

N/A

N/A
SICK 0.00 % 0.95 %

N/A

N/A
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

N/A

N/A
HHL:CA Harvest Healthcare Leader.. 0.00 % 1.15 %

N/A

N/A
CIND:LSE iShares VII PLC - iShares.. 0.00 % 0.00 %

N/A

USD 1.55B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

N/A
IUHC:LSE iShares S&P 500 USD Healt.. 0.00 % 0.00 %

N/A

USD 2.40B
SXLV:LSE SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

N/A

N/A
VMVL:LSE 0.00 % 0.00 %

N/A

N/A
WQDS:LSE iShares MSCI World Qualit.. 0.00 % 0.00 %

N/A

N/A
WQDV:LSE iShares MSCI World Qualit.. 0.00 % 0.00 %

N/A

N/A
XLDX:LSE Xtrackers LevDAX Daily Sw.. 0.00 % 0.00 %

N/A

N/A
XSHC:LSE Xtrackers MSCI USA Health.. 0.00 % 0.00 %

N/A

USD 0.65B
XUHC:LSE Xtrackers MSCI USA Health.. 0.00 % 0.00 %

N/A

USD 0.65B
EXI3:F iShares Dow Jones Industr.. 0.00 % 0.00 %

N/A

N/A
GNAR:F 0.00 % 0.00 %

N/A

N/A
MJMT:F Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

N/A
QDVG:F iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

N/A
QDVW:F iShares MSCI World Qualit.. 0.00 % 0.00 %

N/A

N/A
GNAR:XETRA 0.00 % 0.00 %

N/A

N/A
VMVL:XETRA 0.00 % 0.00 %

N/A

N/A
OUFH:XETRA 0.00 % 0.00 %

N/A

N/A
ESNG 0.00 % 0.00 %

N/A

N/A
HHL-B:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

N/A

N/A
TDOC:CA TD Global Healthcare Lead.. 0.00 % 0.00 %

N/A

CAD 0.08B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B
WELG:XETRA Amundi S&P Global Health .. 0.00 % 0.00 %

N/A

N/A
WELS:XETRA Amundi S&P Global Health .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.23% 40% F 74% C
Dividend Return 1.83% 75% C 77% C+
Total Return 6.05% 40% F 76% C+
Trailing 12 Months  
Capital Gain -11.18% 40% F 43% F
Dividend Return 3.03% 50% F 61% D-
Total Return -8.15% 50% F 44% F
Trailing 5 Years  
Capital Gain 19.98% 57% F 54% F
Dividend Return 17.79% 60% D- 53% F
Total Return 37.76% 57% F 55% F
Average Annual (5 Year Horizon)  
Capital Gain 6.80% 80% B- 61% D-
Dividend Return 9.85% 90% A- 64% D
Total Return 3.05% 60% D- 68% D+
Risk Return Profile  
Volatility (Standard Deviation) 14.75% 80% B- 83% B
Risk Adjusted Return 66.79% 90% A- 87% B+
Market Capitalization 151.21B 88% B+ 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.